Advanced glycation end products (AGEs) and the interaction with their receptors (RAGE) play an important role in the pathogenesis of diabetic foot (DF) associated with diabetic neuropathy. Our study examined the association between asymmetric dimethyl arginine (ADMA), fructosamine, nitric oxide (NO), and soluble (s) RAGE levels in serum of diabetic patients with and without neuropathy.
Methods
Circulating levels of ADMA, fructosamine, NO, and sRAGE, estimated either chemically or by enzyme-linked immunosorbent assay, were examined in 60 type 2 diabetes mellitus (T2DM) overweight/obese (body mass index, 30.5 ± 1.5 kg/m2) male patients and 20 age-matched (55 ± 3 years) obese healthy subjects as control group. The T2DM subjects were categorized as patients without DF (n = 30), and the remaining were patients with DF associated with neuropathy.
Results
First sRAGE levels were significantly increased in T2DM patients without DF in comparison to healthy controls (1656.6 [1198.8-2065.4] vs 1111.7 [909-1605.3] pg/mL, respectively; P < 0.05). However, in the DF group (1049.6 [783.7-1221.8] pg/mL), its level decreased significantly in comparison to both groups (P < 0.05). However, ADMA and fructosamine were significantly higher in diabetic patients with DF than both T2DM without DF and healthy controls. Moreover, NO was significantly lower in DF than in diabetic patients without DF and controls (5 ± 0.4 and 8 ± 0.4 vs 42 ± 2.5 μmol/L, respectively; P < 0.05). Finally, sRAGE levels were significantly correlated with ADMA, fructosamine, and NO.
Conclusions
Soluble forms of the receptor for advanced glycation end product could be an endogenous protection factor against occurrence of DF, hence may be of therapeutic value in the treatment of DF.
WongMC, ChungJW, WongTK.Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007; 335: 387.
2.
MekkesJR, LootsMAM, VanDerWalAC. Causes, investigation and treatment of leg ulceration. Br J Dermatol. 2003; 148: 388–401.
3.
VardiM, NiniA.Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007;1.
4.
Sanchez-RamirezGM, Caram-SalasNL, Rocha-GonzalezHI.Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 2006; 13: 530(1-2), 48–53.
5.
YokoiM, YamagishiS, TakeuchiM. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol. 2007; 91: 397–405.
6.
American Diabetes Association. Standards of Medical Care in Diabetes. Prevention and Management of Diabetes Complications, Neuropathy screening and treatment Diabetes Care2011; S27.
7.
El-MesallamyHO, HammadLN, El-MamounTA. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J Diabetes Complications. 2011; 25: 168–174.
8.
NessarA.Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005; 67: 3–21.
9.
HumpertPM, DjuricZ, KopfS. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007; 7 (6): 9–14.
10.
HudsonBI, HarjaE, MoserB. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?Arterioscler Thromb Vasc Biol. 2005; 25 (5): 879–882.
11.
GeroldiD, FalconeC, EmanueleE.Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006; 13 (17): 1971–1978.
12.
DeGennaro CV, BianchiM, PascaleV. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit. 2009; 15 (4): 91–101.
13.
WagnerFW.Supplement: algorithms of foot care. In:LevinME, O'NealLW, eds.The Diabetic Foot. 3rd ed. St. Louis, MO: CV. Mosby; 1983: 291–302.
14.
BelliziniMC, DietzWH.Workshop on childhood obesity: summary of the discussion. Am J Clin Nutr. 1999; 70 (suppl): 173S–175S.
15.
TrinderP.Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969; 22: 158–161.
16.
RichmondW.Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973; 19: 1350–1356.
17.
BursteinM, ScholnickHR, MorfinR.Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11: 583–595.
GreenLC, WagnerDA, GlogowskiJ. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982; 126 (1): 131–138.
20.
BakerJ R, RogerN, JohnsonPA.Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta. 1983; 127 (1): 87–95.
21.
AbrahamEC, HuffTA, CopeND. Determination of the glycosylated hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes. 1978; 27: 931–937.
22.
BraunwaldE, FauciAS, KasperDL.Harrison Principles of Internal Medicine. 15th ed. New York, NY: McGraw- Hill; 2001.
23.
VinikAI.Diabetic neuropathies. Med Clin North Am. 2004; 88 (4): 947–999.
24.
EckmanAS. Diabetic Neuropathy (Nerve Damage) and Diabetes. American Diabetes Association (ADA): 2010. Additional Specific Types of Diabetic Neuropathy. National Diabetes Education Program: Prevention and Early Intervention for Diabetes Foot Problems.
25.
YonemA, DuranC, UnalM. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract. 2009; 84: 219–223.
26.
CasperGS, CoenDAS. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005; 109: 143–159.
27.
SchalkwijkCG, StehouwerCD.Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005; 109: 143–159.
28.
PereiraEC, FerderbarS, BertolamiMC. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem. 2008; 41: 1454–1460.
29.
WilliamsSB, CuscoJA, RoddyMA.Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 1996; 27: 567–574.
30.
VevesA, AkbariCM, PrimaveraJ.Endothelial dysfunction and the expression of endothelial nitric oxide synthase in diabetic neuropathy, vascular disease and foot ulceration. Diabetes. 1998; 47: 457–463.
31.
PalmerRM, ReesDD, AshtonDS. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem Biophys Res Commun. 1988; 153: 1251–1256.
32.
KocF, TokacM, ErdemS. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit. 2010; 16 (11): CR536–CR539.
33.
VallejoS, AnguloJ, PeiroC. Highly glycated oxyhemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia. 2000; 43: 83–90.
34.
FeldmanEC, NelsonRW.Canine Diabetes Mellitus. InCanine and Feline Endocrinology and Reproduction. 3rd ed.St. Louis, MO: Saunders; 2004: 510.
35.
WautierMP, BoulangerE, GuillausseauPJ. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb Haemost. 2004; 91: 879–885.
36.
SparveroLJ, Asafu-AdjeiD, KangR. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. J Transl Med. 2009; 17: 7–17.
37.
DiegoG, ColombaF, EnzoE. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005; 23 (9): 1725–1729.
38.
FunabikiK, TominoY.Increased serum endogenous secretory receptor for advanced glycation endproduct (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008; 81: 196–201.
39.
Maillard-LefebvreH, BoulangerE, DarouxM. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology. 2009; 48: 1190–1196.
40.
ThornalleyPJ.Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002; 50: 37–57.
41.
LukicIK, HumpertPM, NawrothPP. The RAGE pathway. Ann N Y Acad Sci. 2008; 1126: 76–80.
42.
GohS-Y, CooperME.The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008; 93 (4): 1143–1152.
43.
GrossinN, WautierMP, MeasbT.Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008; 34: 392–395.
44.
GohdaT, TanimotoM, MoonJ-Y. Increased serum endogenous secretory receptor for advanced glycation endproduct (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008; 81: 196–201.
